Evommune (EVMN) Research & Development (2024 - 2026)

Evommune (EVMN) has 3 years of Research & Development data on file, last reported at $6.7 million in Q1 2026.

• On a quarterly basis, Research & Development rose 64.46% year-over-year to $6.7 million in Q1 2026; TTM through Mar 2026 was $60.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $74.0 million, up 15.25% from the prior year.
• Research & Development for Q1 2026 stood at $6.7 million, down from $29.9 million in the prior quarter.
• Over the last five years, Research & Development for EVMN reached as high as $57.5 million in Q4 2024 and fell as low as $2.8 million in Q3 2024.
• Historically, Research & Development has averaged $20.1 million across 3 years, with a median of $13.2 million in 2025.
• On a YoY basis, Research & Development climbed as much as 600.39% in 2025 and fell as far as 47.96% in 2025.
• Year by year, Research & Development stood at $57.5 million in 2024, then sank by 47.96% to $29.9 million in 2025, then tumbled by 77.72% to $6.7 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $6.7 million in Q1 2026, $29.9 million in Q4 2025, and $19.6 million in Q3 2025.